3rd ADC Target Selection Summit

With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returns as the only industry-specific meeting spotlighting the latest developments in the field that will continue progressing first- and best-in-class ADCs through the clinic.

Providing a greater focus on identifying and validating novel targets, re-examining what makes a good target, and analyzing how novel linker-payload technologies are changing the target selection paradigm; this is your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.

With 100+ ADC enthusiasts set to be in the room including Iksuda Therapeutics, Merck and Co, Angiex, Ziel Bio, and Seagen; this is your chance to connect with peers working exclusively in biology, discovery, translational, target identification and validation.